Key Highlights

● Citius Oncology, the roughly 71%-owned subsidiary of Citius Pharmaceuticals, reported $5.6 million in first-half fiscal 2026 LYMPHIR revenue and near-universal commercial payer coverage, even as both companies lean on recent financings to fund operations only through November 2026.

● At the parent level, Citius Pharma held $4.6 million in cash as of March 31, 2026, before closing a $5 million registered direct offering on April 24, 2026.

● Both companies explicitly guide to a runway lasting only through November 2026, and a meaningful share of a new financing facility is contingent on revenue milestones or stock conditions.

● Investors should watch for LYMPHIR revenue and payer-coverage figures in Citius Oncology's fiscal third-quarter 2026 report.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) does not sell LYMPHIR itself. That job belongs to Citius Oncology, Inc. (Nasdaq: CTOR), the majority-owned subsidiary Citius Pharma spun out to commercialize the cutaneous T-cell lymphoma therapy denileukin diftitox-cxdl. On May 15, 2026, the two companies reported fiscal second-quarter results in tandem: Citius Oncology disclosed $1.7 million in LYMPHIR net product revenue for the quarter and $5.6 million for the first half of fiscal 2026, alongside broadening payer coverage. Citius Pharma, which owns approximately 71% of Citius Oncology, reported its own steep net loss, driven largely by a one-time contract-cancellation charge, and disclosed a combined cash runway that both companies say extends only through November 2026.

What happened

Citius Oncology's fiscal Q2 (three months ended March 31, 2026) results showed LYMPHIR generating $1.7 million in net revenue at roughly 80% gross margin, bringing first-half revenue to $5.6 million. The company reported a Q2 net loss of $26.6 million, driven substantially by a $19.7 million charge tied to cancellation of a contract manufacturing agreement, and held $2.6 million in cash as of March 31, 2026. Citius Pharma's parent-level filing, released the same day, showed a Q2 net loss of $21.2 million ($0.95/share) and a six-month net loss of $29.5 million ($1.34/share), with $4.6 million in parent-level cash. Separately, on March 31, 2026, Citius Oncology's commercial update cited roughly 135 health plans covering approximately 80% of lives, 83% of target accounts with LYMPHIR added to or under formulary review, and no reported reimbursement denials. On May 5, 2026, Citius Oncology announced up to $36.5 million in new debt and equity: a senior secured facility of up to $25 million from Avenue Capital ($10 million funded at closing, up to $15 million more tied to revenue milestones), plus roughly $11.5 million from exercising existing warrants. Citius Pharma separately closed a $5 million registered direct offering on April 24, 2026.

Why the development matters

LYMPHIR's revenue and payer-coverage trajectory are early but real signs of commercial traction, a milestone many small biotechs never reach. Near-universal payer coverage with zero reported denials, if it holds, would de-risk a reimbursement pathway that historically constrains niche oncology launches. However, both companies remain cash-constrained: the November 2026 runway guidance means further raises are likely within months, and much of the $36.5 million facility is conditional, on revenue milestones for the debt tranches and stockholder approval for the warrants, meaning the full amount is not yet in hand.

Company and product background

Citius Pharmaceuticals is a specialty pharmaceutical company with three principal assets. LYMPHIR, an IL-2-diphtheria toxin fusion protein for relapsed or refractory cutaneous T-cell lymphoma, received FDA approval in 2024 and is commercialized through Citius Oncology, in which Citius Pharma holds a majority (~71%) equity stake; the two trade as separate Nasdaq-listed securities, CTXR and CTOR. Citius Pharma's wholly owned pipeline includes Mino-Lok, an antibiotic lock solution to salvage infected central venous catheters, which completed a Phase 3 trial in 2023 that the company says met its endpoints, and Halo-Lido (CITI-002), a topical lidocaine formulation for hemorrhoid-related pain that completed a Phase 2b trial the same year. Both remain in "continued FDA engagement," with no confirmed filing or approval timeline disclosed. On the LYMPHIR side, Citius Oncology has pursued incremental clinical expansion, including a first international shipment to Europe via a named-patient distribution partner (April 29, 2026) and an investigator-initiated combination study with pembrolizumab in gynecologic malignancies, reporting a 24% objective response rate and 48% clinical benefit rate in a small evaluable-patient cohort presented at ASCO 2026.

Financial position

At the parent level, Citius Pharma held $4.6 million in cash as of March 31, 2026, before closing a $5 million registered direct offering on April 24, 2026. Six-month net loss was $29.5 million, though a large portion, a $19.7 million CMO contract-cancellation charge recorded at the Citius Oncology level, is non-recurring. Citius Oncology separately held $2.6 million in cash as of the same date and, in early May, arranged up to $36.5 million in debt and equity: $10 million funded immediately under an Avenue Capital facility (up to $25 million total, remaining $15 million contingent on revenue milestones), plus roughly $11.5 million from warrant exercises at $0.90/share, with additional warrant tranches subject to stockholder approval. Both companies stated combined resources are expected to fund operations only through November 2026, a company-provided estimate, implying further raises are likely before year-end. As of late July 2026, CTXR traded near $0.53/share with roughly 27.5 million shares outstanding (~$14.6 million market cap), while CTOR traded near $0.55/share with about 93.0 million shares outstanding (~$50.7 million market cap).

Bull case

LYMPHIR's first two quarters of sales, expanding payer coverage, zero reported denials, and a first international shipment suggest the commercial launch is proceeding without the reimbursement friction that often stalls niche oncology products. Fresh capital from Avenue Capital, paired with warrant-exercise proceeds, buys time without an immediate follow-on equity raise at depressed prices. Early combination-therapy signals in gynecologic cancers, though from a small investigator-led study, could expand LYMPHIR's addressable use if confirmed in larger trials.

Risk case

Both companies explicitly guide to a runway lasting only through November 2026, and a meaningful share of the new $36.5 million facility is contingent on revenue milestones or stockholder approval that may not materialize on schedule. LYMPHIR's revenue base remains small relative to operating costs, and the $19.7 million CMO charge signals ongoing volatility in manufacturing arrangements. Citius Pharma's wholly owned pipeline assets, Mino-Lok and Halo-Lido, have no confirmed regulatory filing timeline despite completed pivotal-stage trials, and continued dilution, through warrant exercises, new offerings, or debt-conversion features in the Avenue facility, remains a persistent risk for shareholders in both CTXR and CTOR.

What investors should watch next

Key measurable catalysts include: LYMPHIR revenue and payer-coverage figures in Citius Oncology's fiscal Q3 2026 report; drawdown and milestone achievement under the remaining $15 million Avenue Capital tranche; stockholder approval of the additional warrant issuances tied to the May financing; any regulatory update on Mino-Lok or Halo-Lido; and updated cash-runway guidance beyond the current November 2026 estimate.

Conclusion

Citius Oncology's early LYMPHIR sales and payer-coverage data offer tangible evidence of commercial progress, but both it and majority owner Citius Pharmaceuticals remain thinly capitalized, with funding visibility extending only a few months out. The near-term path hinges on whether reimbursement momentum continues, whether conditional financing tranches convert into actual cash, and whether the wholly owned pipeline assets eventually reach the FDA. Investors should weigh confirmed commercial traction against explicit, near-term liquidity constraints disclosed by management.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.